Related Experiment Video
Updated: Apr 18, 2026
Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity
Published on: August 23, 2022
FLZ attenuates learning and memory deficits via suppressing neuroinflammation induced by LPS in mice
Liang-Yu Wu1, Xiu-Qi Bao, Hong-Yan Pang
1a State Key Laboratory of Bioactive Substance and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100050 , China.
Abstract:
Alzheimer's disease (AD) is the most common neurodegenerative disorder in which neuroinflammation plays an important role. FLZ is a novel synthetic derivative of natural squamosamide. Previous studies demonstrated that FLZ had neuroprotective effects on AD models and showed strong anti-inflammatory property in Parkinson's disease models. However, whether the neuroprotective effects of FLZ on AD are associated with its anti-inflammatory property is still not fully elucidated. In this study, we aimed to investigate the ability of FLZ in modulating inflammation. The results showed that FLZ significantly improved memory deficits and alleviated neuronal damage as well as neuronal loss in the hippocampus of mice intracerebroventricular injected with lipopolysaccharide (LPS). Mechanistic studies revealed that the neuroprotective effects of FLZ were due to the suppression of neuroinflammation induced by LPS, as indicated by inactivation of astrocytes and microglia, reduced production of tumor necrosis factor-α, interleukin-1β, and nitric oxide, as well as decreased expression of cyclooxygenase-2 and inducible nitric oxide synthase. The beneficial effects of FLZ on AD were further supported by the finding that FLZ attenuated β-amyloid production through inhibiting β-amyloid precursor protein cleaving enzyme 1 expression. These results suggested that anti-inflammatory agent could be useful for the treatment of AD.
Insights
FLZ, an anti-inflammatory agent, improved memory and neuronal loss in Alzheimer's disease models by reducing neuroinflammation and beta-amyloid production. This suggests FLZ
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Alzheimer's disease (AD) is a prevalent neurodegenerative disorder where neuroinflammation is a key factor.
- FLZ, a synthetic derivative of squamosamide, exhibits neuroprotective and anti-inflammatory properties.
- The precise mechanism linking FLZ's neuroprotective effects in AD to its anti-inflammatory actions requires further elucidation.
Purpose of the Study:
- To investigate the anti-inflammatory capacity of FLZ in Alzheimer's disease models.
- To determine if FLZ's neuroprotective effects in AD are mediated by its anti-inflammatory properties.
Main Methods:
- Administered FLZ to mice intracerebroventricularly injected with lipopolysaccharide (LPS) to induce AD-like pathology.
- Assessed memory deficits, neuronal damage, and loss in the hippocampus.
- Analyzed the expression of inflammatory markers (TNF-α, IL-1β, NO, COX-2, iNOS) and β-amyloid precursor protein cleaving enzyme 1 (BACE1).
Main Results:
- FLZ significantly improved memory deficits and reduced neuronal damage and loss in LPS-treated mice.
- FLZ suppressed LPS-induced neuroinflammation by inactivating astrocytes and microglia and reducing pro-inflammatory mediators.
- FLZ attenuated β-amyloid production by inhibiting BACE1 expression.
Conclusions:
- FLZ demonstrates significant neuroprotective effects in an AD mouse model, primarily through the suppression of neuroinflammation.
- FLZ reduces both neuroinflammation and β-amyloid pathology, highlighting its potential as a therapeutic agent for Alzheimer's disease.
- These findings support the therapeutic potential of anti-inflammatory agents for treating Alzheimer's disease.
